About Scholar Rock Holding Corp
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://scholarrock.com/
Frequently Asked Questions
What is the 52-week range for SRRK?
The 52-week high is $61.76 and the 52-week low is $27.07.
What is the P/E ratio for SRRK?
The P/E ratio data is currently unavailable.
What is the dividend yield for SRRK?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -159.12%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -236.96%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 18.30.
Analyst Recommendation Trends
Wall Street analyst consensus for SRRK over the last few months:
Latest SRRK News
3 drug targets pharma is betting on next
Companies including GSK, Merck, Roche and Sanofi are pushing new approaches in cancer and inflammatory diseases.
FDA Decision Watch: BMY, EGTX Face Key Decisions This Week As BFRI, SRRK And MIRM Score Early Approvals
Bristol Myers Squibb and Egetis await FDA decisions on treatments for heart and rare genetic conditions, while Scholar Rock, Biofrontera and Mirum have already secured regulatory wins ahead of schedule.
Scholar Rock Poised for De-risked Commercial Ramp in Neuromuscular Space, Wedbush Says
Scholar Rock (SRRK) is well positioned for a durable, de-risked commercial ramp in the neuromuscular
Truist Securities Maintains Buy on Scholar Rock Holding, Raises Price Target to $77
Truist Securities analyst Srikripa Devarakonda maintains Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raises the price target from $76 to $77.
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., September 21, 2026--Scholar Rock (NASDAQ: SRRK; the "Company") today announced that the company granted inducement equity awards covering an aggregate of 83,102 shares of its common stock to ten newly hired employees, consisting of inducement stock options to purchase an aggregate of 23,801 shares of common stock and inducement restricted stock units, covering an aggregate of 59,301 shares of its common stock.
JP Morgan Maintains Overweight on Scholar Rock Holding, Raises Price Target to $70
JP Morgan analyst Tessa Romero maintains Scholar Rock Holding (NASDAQ:SRRK) with a Overweight and raises the price target from $63 to $70.
This week in charts: GSK’s China deals, the $300M IPO club and selling the news
The latest installment in BioPharma Dive’s new visualization-focused series features a stock sell-off that confused Wall Street analysts and a closer look at an industry-leading partnership streak.
Scholar Rock Holding (SRRK) Wins FDA Approval for ISEMBYLD. Can Add-On Use Scale?
Scholar Rock Holding Corporation (NASDAQ:SRRK) secured FDA approval on September 11 for ISEMBYLD, apitegromab-mstn, to treat spinal muscular atrophy in adults and children aged two and older currently receiving survival motor neuron 2 (SMN2)-targeted therapy. Approval opens a commercial opportunity built around adding muscle-directed treatment to existing care. The investment question now shifts to how […]
Scholar Rock (SRRK) Stock Fair Value Edges Higher After Isembyld Approval And Analyst Revisions
Scholar Rock Holding now carries a slightly higher modelled fair value, shifting from US$59.31 to US$62.06. This places it in line with the low to mid US$60s price targets cited in recent research. Street commentary around the Isembyld approval, updated adoption assumptions and the US$63 JPMorgan target helps explain why analysts are comfortable anchoring expectations around this new level. As you read on, you will see how these evolving targets and the surrounding narrative might shape your...
Scholar Rock Faces Early Isembyld Launch Friction From FDA Safety Requirements, Truist Says
Scholar Rock (SRRK) could face some friction during the early commercialization of Isembyld after th
Scholar Rock: Reiterating 'Strong Buy' On FDA Approval SMA And Expansions Now In Play
FDA approval of Scholar Rockâs ISEMBYLD (apitegromab) for SMA drives a Strong Buy case, with $2B+ market upside and EU/JP catalysts. Click for more on SRRK stock.
Evercore ISI Group Maintains Outperform on Scholar Rock Holding, Raises Price Target to $72
Evercore ISI Group analyst Cory Kasimov maintains Scholar Rock Holding (NASDAQ:SRRK) with a Outperform and raises the price target from $65 to $72.
Piper Sandler Maintains Overweight on Scholar Rock Holding, Raises Price Target to $75
Piper Sandler analyst Allison Bratzel maintains Scholar Rock Holding (NASDAQ:SRRK) with a Overweight and raises the price target from $60 to $75.
Jefferies Maintains Buy on Scholar Rock Holding, Raises Price Target to $65
Jefferies analyst Amy Li maintains Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raises the price target from $57 to $65.
This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Analysts downgraded Banco Santander Brasil, Ribbon Communications, Cellectis, Scholar Rock, with mixed price-target changes.
Wedbush Maintains Outperform on Scholar Rock Holding, Raises Price Target to $70
Wedbush analyst David Nierengarten maintains Scholar Rock Holding (NASDAQ:SRRK) with a Outperform and raises the price target from $64 to $70.
Zebra Technologies To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday
Analysts cut Exodus’ target, raised targets for Teledyne, Roblox, Scholar Rock, Zebra, Agilon, SM Energy and Paymentus; Agilon upgraded to Outperform.
Barclays Downgrades Scholar Rock Holding to Equal-Weight, Raises Price Target to $58
Barclays analyst Etzer Darout downgrades Scholar Rock Holding (NASDAQ:SRRK) from Overweight to Equal-Weight and raises the price target from $55 to $58.
HC Wainwright & Co. Maintains Buy on Scholar Rock Holding, Raises Price Target to $70
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raises the price target from $65 to $70.
Scholar Rock Marks 'Defining Moment' with First Muscle-Targeted Treatment for Spinal Muscular Atrophy
The U.S. Food and Drug Administration on Friday approved ISEMBYLD (apitegromab-mstn) from Scholar Rock for spinal muscular atrophy (SMA) in adults and pediatric patients aged 2 years and older. The decision makes ISEMBYLD the first muscle-targeted therapy to demonstrate motor...
SRRK Shares Pull Back After FDA Approval For Genetic Disease Drug — But Wall Street Hikes Price Targets
On a call on Monday, the company set a list price of $11,659 per vial of Isembyld, or about $310,000 a year for a typical patient.
Scholar Rock's Early FDA Approval on Spinal Muscular Atrophy Drug Seen as 'Positive Surprise,' UBS Says
Scholar Rock Holding (SRRK) won early regulatory approval of Isembyld to treat spinal muscular atrop
Scholar Rock Holding Corporation (SRRK) Discusses FDA Approval and Clinical Impact of ISEMBYLD in SMA Treatment Transcript
Scholar Rock Holding Corporation (SRRK) Discusses FDA Approval and Clinical Impact of ISEMBYLD in SMA Treatment September 14, 2026 8:00 AM EDTCompany...
Raymond James Maintains Strong Buy on Scholar Rock Holding, Raises Price Target to $72
Raymond James analyst Gary Nachman maintains Scholar Rock Holding (NASDAQ:SRRK) with a Strong Buy and raises the price target from $65 to $72.
BMO Capital Maintains Outperform on Scholar Rock Holding, Raises Price Target to $84
BMO Capital analyst Etzer Darout maintains Scholar Rock Holding (NASDAQ:SRRK) with a Outperform and raises the price target from $76 to $84.
Truist Securities Reiterates Buy on Scholar Rock Holding, Raises Price Target to $76
Truist Securities analyst Srikripa Devarakonda reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raises the price target from $55 to $76.
Scholar Rock Shares Rise 9.1% After FDA Approves ISEMBYLD for Spinal Muscular Atrophy
Scholar Rock Holding Corp (NASDAQ:SRRK) shares rose 9. 1% in pre-market trading to $60.
Premarket movers: AI stocks slide on warnings, Rumble, Scholar Rock jump
Investing.com - U.S. stock index futures fell sharply on Monday, with technology stocks under pressure after several leading artificial intelligence executives called for a slower pace of AI development amid concerns over potential risks from the technology.
Citigroup Maintains Buy on Scholar Rock Holding, Raises Price Target to $74
Citigroup analyst Geoff Meacham maintains Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raises the price target from $60 to $74.
Scholar Rock SMA drug approved by FDA
Projected by some analysts as a future blockbuster, Isembyld is the first “muscle-targeted” treatment for the disease and, in clinical testing, helped improve motor function in people on standard therapies.
Wedbush Reiterates Outperform on Scholar Rock Holding, Maintains $64 Price Target
Wedbush analyst David Nierengarten reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Outperform and maintains $64 price target.
Scholar Rock Exec Says Its First Drug To Target Muscle Loss In Spinal Muscular Atrophy Has A Wholesale Acquisition Cost Of $11,659 For A Single Use Vial; Exec Says Co Expects The Annual Net Cost In The U.S. For A Typical Patient To Be ~$310,000
- Conference Call
Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Scholar Rock surged 11.9% after FDA approved ISEMBYLD for SMA; Scinai, Intercont and Rum led premarket gainers, while Picocela fell.
Second Time’s The Charm: FDA Clears Scholar Rock’s SMA Drug Ahead Of Deadline, SRRK Soars 15% After-Hours
FDA approved Isembyld for patients age two and older who already take certain spinal muscular atrophy drugs.
Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)
CAMBRIDGE, Mass., September 11, 2026--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology, today announced that the FDA has approved ISEMBYLD (apitegromab-mstn) for the treatment of spinal muscular atrophy (SMA) in adults and children two years of age and older who are currently receiving a survival motor neuron 2 (SMN2)-targete
FDA Approves First Therapy To Target Muscle Loss In Spinal Muscular Atrophy In Patients Aged 2 Years And Older
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-therapy-target-muscle-loss-spinal-muscular-atrophy
Scholar Rock Holding Corporation (SRRK) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Scholar Rock Holding Corporation (SRRK) Citigroup's Biopharma Back to School Summit 2026 September 10, 2026 9:20 AM EDTCompany ParticipantsDavid Hallal -...
HC Wainwright & Co. Reiterates Buy on Scholar Rock Holding, Maintains $65 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Buy and maintains $65 price target.
Scholar Rock: Manufacturing Noise Obscures A Muscle-Targeted Franchise
Scholar Rock (SRRK) nears FDA decision on apitegromab for SMA by Sept 30, 2026; see SAPPHIRE data, manufacturing risks, and valuation outlookâread now.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-24 | Woods Keith | -48,034 | - | - |
| 2026-09-21 | Hallal David | -36,652 | - | - |
| 2026-07-01 | FLIER JEFFREY S. | -15 | $54.8757 | $823 |
| 2026-07-01 | FLIER JEFFREY S. | -1,470 | $54.2365 | $79,728 |
| 2026-07-01 | FLIER JEFFREY S. | -1,568 | $53.5328 | $83,939 |
| 2026-07-01 | Reed Joshua | -948 | $54.2814 | $51,459 |
| 2026-07-01 | Reed Joshua | -2,105 | $53.4958 | $112,609 |
| 2026-07-01 | Peng Katie | -21 | $54.9641 | $1,154 |
| 2026-07-01 | Peng Katie | -2,437 | $54.2526 | $132,214 |
| 2026-07-01 | Peng Katie | -2,988 | $53.5598 | $160,037 |
| 2026-07-01 | Burow Kristina | -948 | $54.2816 | $51,459 |
| 2026-07-01 | Burow Kristina | -2,105 | $53.494 | $112,605 |
| 2026-07-01 | Gilman Michael | -43 | $54.8145 | $2,357 |
| 2026-07-01 | Gilman Michael | -1,155 | $54.2257 | $62,631 |
| 2026-07-01 | Gilman Michael | -1,346 | $53.544 | $72,070 |
| 2026-06-04 | FLIER JEFFREY S. | +4,310 | - | - |
| 2026-06-04 | FLIER JEFFREY S. | +6,839 | - | - |
| 2026-06-04 | Reed Joshua | +4,310 | - | - |
| 2026-06-04 | Reed Joshua | +6,839 | - | - |
| 2026-06-04 | Peng Katie | +4,310 | - | - |
| 2026-06-04 | Peng Katie | +6,839 | - | - |
| 2026-06-04 | Brudnick Richard | +4,310 | - | - |
| 2026-06-04 | Brudnick Richard | +6,839 | - | - |
| 2026-06-04 | Burow Kristina | +4,310 | - | - |
| 2026-06-04 | Burow Kristina | +6,839 | - | - |
| 2026-06-04 | Gilman Michael | +4,310 | - | - |
| 2026-06-04 | Gilman Michael | +6,839 | - | - |
| 2026-06-04 | AKKARAJU SRINIVAS | +4,310 | - | - |
| 2026-06-04 | AKKARAJU SRINIVAS | +6,839 | - | - |
| 2026-04-23 | Burow Kristina | -18,000 | - | - |
| 2026-04-23 | Burow Kristina | -36,000 | - | - |
| 2026-04-23 | Burow Kristina | -28,000 | - | - |
| 2026-04-23 | Burow Kristina | -7,800 | - | - |
| 2026-04-23 | Burow Kristina | +18,000 | $8.36 | $150,480 |
| 2026-04-23 | Burow Kristina | +36,000 | $9.11 | $327,960 |
| 2026-04-23 | Burow Kristina | +28,000 | $4.75 | $133,000 |
| 2026-04-23 | Burow Kristina | +7,800 | $26.78 | $208,884 |
| 2026-04-16 | Woods Keith | -10,220 | $49.5745 | $506,651 |
| 2026-04-16 | Vaishnaw Akshay | -12,246 | $49.5745 | $607,089 |
| 2026-04-16 | Hallal David | -30,615 | $49.5745 | $1,517,723 |
| 2026-04-16 | Sinha Vikas | -10,410 | $49.5745 | $516,071 |
| 2026-02-23 | Qatanani Mo | -200 | $48.48 | $9,696 |
| 2026-02-23 | Qatanani Mo | -857 | $47.8588 | $41,015 |
| 2026-02-23 | Qatanani Mo | -7,427 | $46.9422 | $348,640 |
| 2026-02-17 | Qatanani Mo | -7,989 | $46.5282 | $371,714 |
| 2026-02-17 | Parlavecchio Caryn | -9,035 | $46.5282 | $420,382 |
| 2026-02-17 | Ho Junlin | -9,580 | $46.5282 | $445,740 |
| 2026-02-17 | Marantz Jing L. | -4,157 | $46.5282 | $193,418 |
| 2026-02-09 | Qatanani Mo | +29,258 | - | - |
| 2026-02-09 | Parlavecchio Caryn | +29,258 | - | - |
| 2026-02-09 | Marantz Jing L. | +34,482 | - | - |
| 2026-02-09 | Ho Junlin | +36,572 | - | - |
| 2026-02-09 | Woods Keith | +47,021 | - | - |
| 2026-02-09 | Vaishnaw Akshay | +47,021 | - | - |
| 2026-02-09 | Hallal David | +128,004 | - | - |
| 2026-02-09 | Sinha Vikas | +47,021 | - | - |
| 2026-01-22 | Qatanani Mo | -12,779 | $46.8541 | $598,749 |
| 2026-01-22 | Qatanani Mo | -2,119 | $45.8655 | $97,189 |
| 2026-01-16 | Qatanani Mo | -8,406 | $44.4777 | $373,880 |
| 2026-01-16 | Parlavecchio Caryn | -6,600 | $44.4777 | $293,553 |
| 2026-01-16 | Ho Junlin | -8,016 | $44.4777 | $356,533 |
| 2026-01-16 | Marantz Jing L. | -5,798 | $44.4777 | $257,882 |
| 2026-01-14 | Qatanani Mo | -2,678 | - | - |
| 2026-01-14 | Qatanani Mo | -5,893 | - | - |
| 2026-01-14 | Qatanani Mo | -2,813 | - | - |
| 2026-01-14 | Qatanani Mo | -321 | - | - |
| 2026-01-14 | Qatanani Mo | -1,407 | - | - |
| 2026-01-14 | Qatanani Mo | -13,112 | $45.1961 | $592,611 |
| 2026-01-14 | Qatanani Mo | +2,678 | $35.15 | $94,132 |
| 2026-01-14 | Qatanani Mo | +5,893 | $15.75 | $92,815 |
| 2026-01-14 | Qatanani Mo | +2,813 | $10 | $28,130 |
| 2026-01-14 | Qatanani Mo | +321 | $7.62 | $2,446 |
| 2026-01-14 | Qatanani Mo | +1,407 | $18.08 | $25,439 |
| 2026-01-13 | Woods Keith | -16,746 | $42.7 | $715,054 |
| 2026-01-13 | Vaishnaw Akshay | -20,438 | $42.7 | $872,703 |
| 2026-01-13 | Hallal David | -57,450 | $42.7 | $2,453,115 |
| 2026-01-13 | Sinha Vikas | -16,755 | $42.7 | $715,439 |
| 2025-12-16 | Peng Katie | -280 | $44.6344 | $12,498 |
| 2025-12-16 | Peng Katie | -726 | $43.8761 | $31,854 |
| 2025-12-12 | AKKARAJU SRINIVAS | -1,064,804 | - | - |
| 2025-12-12 | AKKARAJU SRINIVAS | +1,064,804 | $7.35 | $7,826,309 |
| 2025-12-11 | DEBBANE RAYMOND | -1,575,008 | - | - |
| 2025-12-11 | DEBBANE RAYMOND | +1,575,008 | $7.35 | $11,576,309 |
| 2025-12-04 | Qatanani Mo | -8,035 | - | - |
| 2025-12-04 | Qatanani Mo | -23,571 | - | - |
| 2025-12-04 | Qatanani Mo | -11,250 | - | - |
| 2025-12-04 | Qatanani Mo | -1,281 | - | - |
| 2025-12-04 | Qatanani Mo | -5,607 | - | - |
| 2025-12-04 | Qatanani Mo | -21,093 | - | - |
| 2025-12-04 | Qatanani Mo | -65,625 | - | - |
| 2025-12-04 | Qatanani Mo | -136,462 | $45.2125 | $6,169,788 |
| 2025-12-04 | Qatanani Mo | +8,035 | $35.15 | $282,430 |
| 2025-12-04 | Qatanani Mo | +23,571 | $15.75 | $371,243 |
| 2025-12-04 | Qatanani Mo | +11,250 | $10 | $112,500 |
| 2025-12-04 | Qatanani Mo | +1,281 | $7.62 | $9,761 |
| 2025-12-04 | Qatanani Mo | +5,607 | $4.86 | $27,250 |
| 2025-12-04 | Qatanani Mo | +21,093 | $18.08 | $381,361 |
| 2025-12-04 | Qatanani Mo | +65,625 | $26.05 | $1,709,531 |
| 2025-10-08 | Hallal David | -205,000 | - | - |
| 2025-10-07 | AKKARAJU SRINIVAS | +4,403 | $40.97 | $180,391 |
| 2025-10-07 | AKKARAJU SRINIVAS | +12,400 | $40.18 | $498,232 |
| 2025-10-07 | AKKARAJU SRINIVAS | +12,796 | $39.31 | $503,011 |
| 2025-10-06 | AKKARAJU SRINIVAS | +13,748 | $39.52 | $543,321 |
| 2025-10-06 | AKKARAJU SRINIVAS | +80,863 | $38.68 | $3,127,781 |
| 2025-10-06 | AKKARAJU SRINIVAS | +18,414 | $37.89 | $697,706 |
| 2025-10-03 | AKKARAJU SRINIVAS | +319,700 | $37.42 | $11,963,174 |
| 2025-10-03 | AKKARAJU SRINIVAS | +56,703 | $36.74 | $2,083,268 |
| 2025-10-03 | AKKARAJU SRINIVAS | +11,011 | $35.61 | $392,102 |